Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Vistin Pharma ASA ( (DE:VP4) ) has provided an update.
Vistin Pharma ASA has called its Annual General Meeting for 20 May 2026 at 13:00 CEST, formalizing its regular governance cycle and engaging shareholders in key corporate decisions. The company continues to operate within Norway’s regulated market framework, complying with disclosure rules under the Norwegian Securities Trading Act.
The meeting will be held without physical attendance, requiring shareholders to authorize the Chairman of the Board through proxies, with or without voting instructions, to exercise their voting rights remotely. The election committee’s recommendations and formal notice have been distributed to shareholders and published on the company’s website, underscoring a structured approach to board elections and corporate oversight.
More about Vistin Pharma ASA
Vistin Pharma ASA is a Norway-based pharmaceutical company listed on the Oslo Stock Exchange that focuses on producing active pharmaceutical ingredients and finished dosage forms. The company primarily serves global generic drug manufacturers and healthcare markets with a focus on efficiency, quality, and regulatory compliance in its manufacturing operations.
Average Trading Volume: 14,379
Current Market Cap: NOK984.4M
Find detailed analytics on VP4 stock on TipRanks’ Stock Analysis page.